Login / Signup

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.

Tim PreijersM W F van SpenglerK MeijerK FijnvandraatK FischerF W G LeebeekM H CnossenR A A Mathôt
Published in: European journal of clinical pharmacology (2021)
Best performing LSSs were LSS with samples taken at days 1, 5, 7, and 8 (N9-GP and rFIXFc) and at days 1, 4, 6, and 8 (rIX-FP), respectively.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • prognostic factors
  • peritoneal dialysis
  • patient reported outcomes